Abstract: The invention concerns the use of Lactobacillus casei in a composition for oral administration to enhance immunity specific to pathogenic micro-organisms. Said composition can in particular be a food or a food supplement.

Abstract: The invention concerns lactic acid bacteria strains capable of regulating the production of NO and inflammatory cytokines by enterocytes, depending on the inflammatory condition of said enterocytes. The strains can also be incorporated in food supplements such as fermented dairy products used for regulating inflammatory response and non-specific immunity.

Abstract: The object of the invention is to propose a novel biomarker for stress states, which biomarker is highly meaningful and capable of enabling quantitative measurements to be made of stress levels. To do this, it has been found, surprisingly, that the air at the end of a person's breathing out, known as “alveolar” air, contains fluorine compounds when that person has been subjected to various stress states. More precisely, the present invention provides components based on fluorine compounds, in particular fluorinated chloroalkanes, used as biomarkers of stress states.

Abstract: The object of the invention is to propose a novel biomarker for stress states, which biomarker is highly meaningful and capable of enabling quantitative measurements to be made of stress levels. To do this, it has been found, surprisingly, that the air at the end of a person's breathing out, known as “alveolar” air, contains fluorine compounds when that person has been subjected to various stress states. More precisely, the present invention provides components based on fluorine compounds, in particular fluorinated chloroalkanes, used as biomarkers of stress states.

Abstract: The invention concerns the use of Lactobacillus casei in a composition for oral administration to enhance immunity specific to pathogenic micro-organisms. Said composition can in particular be a food or a food supplement.

Abstract: The invention concerns lactic acid bacteria with anxiolytic properties and not inducing sedative effect. Said lactic acid bacteria are useful in particular for preparing foods or medicines.

Abstract: The invention concerns novel therapeutic uses of heterologous superoxide dismutase (HSD) for preparing medicines for treating diseases in which cell and organic degeneration is observed, and a method for selecting said HSD.

Abstract: L. casei DN 114-001 is a bacterial agent known for its utility in the fermentation of milk products. A fermented milk product comprising as the sole bacterial agent L. casei DN 114-001 is effective in reducing the number of rotavirus associated diarrhea episodes experienced by infants up to 24 months of age. In particular, the number of rotavirus associated diarrhea episodes, as well as their severity and duration is reduced in children receiving milk products fermented with L. casei DN 114-001, present in the fermented milk product in amounts of at least 106 CFU/g. L. casei may be the sole bacterial agent present in the fermented milk product, and yet effective reduction of diarrhea episodes associated with rotavirus infection is obtained.

Abstract: Novel pharmaceutical compositions that are particularly suitable for oral administration of superoxide dismutases (SODs) and that have good bioavailability and therapeutic efficacy. These compositions are made up of a combination of a superoxide dismutase and at least one lipids or proteins. The lipids are exemplified by ceramides, and the proteins are exemplified by prolamines or polymer films based on such prolamines. A pharmaceutically acceptable vehicle can also be included in the composition.